Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.48 |
| ▸ | KDM1A | O60341 | 8/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | BCL6 | P41182 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1317808 | 0.90 | AURKA (0.45) | AURKAPDPK1AURKB | |
| SCHEMBL1318843 | 0.89 | AURKA (0.48) | AURKAPDPK1AURKBKDM1AEGLN2 | |
| SCHEMBL1317620 | 0.88 | CYP11B1 (0.41) | AURKAPDPK1AURKBKDM1ACYP11B1 | |
| SCHEMBL1318715 | 0.85 | AURKA (0.43) | AURKAPDPK1AURKB | |
| SCHEMBL1317785 | 0.84 | PDPK1 (0.42) | AURKAPDPK1AURKBKDM1AEGLN2 | |
| SCHEMBL16966468 | 0.83 | AURKA (0.41) | AURKAPDPK1AURKBKDM1AEGLN2 | |
| SCHEMBL12119839 | 0.81 | AURKA (0.54) | AURKAPDPK1AURKBEGLN2GPR119 | |
| SCHEMBL16966481 | 0.79 | PDPK1 (0.64) | AURKAPDPK1AURKB | |
| SCHEMBL1317210 | 0.79 | PDPK1 (0.75) | AURKAPDPK1AURKB | |
| SCHEMBL16966473 | 0.78 | AURKA (0.52) | AURKAPDPK1AURKBKDM1ACYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697685-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275611-A1 | CHEMICAL COMPOUNDS | PDK1, PDK2, PDK3 | AURKA 298/4885PDPK1 12/4885AURKB 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.